The components of canonical and non-canonical EZH2 pathways were universally expressed in ovarian cancer specimens with a positive expression rate of 81.54% (53/65) for EZH2, 88.89% (48/54) for H3K27Me3, 63.07% (41/65) for pAkt1, and 75.38% (49/65) for pS21EZH2. This evidence concerns the gene EZH2 and ovarian carcinoma.